Clinical trials: Advanced Tumor
Non-small Cell Lung Cancer (NSCLC)
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
This is a double blind, multicentre, randomized, placebo-controlled study. The eligible patients will be randomized to receive gefitinib or placebo at 1:1 ratio.
- Trial name
- INFORM (NCT00770588)
- Testing
- Gefitinib
- Where
- 14 sites in China
- Volunteers
- 296 people
- Sponsor
- AstraZeneca
Advanced Malignancies
A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors
To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of MLN8237 when given by mouth (PO) for a minimum of 7 and a maximum of 21 consecutive days, followed by a 14-day recovery period.
- Trial name
- NCT00500903
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Mesonephric Gynecologic Cancer
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
This study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.
- Trial name
- NCT05787561
- Testing
- Avutometinib (VS-6766), Defactinib
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Renal Cell Carcinoma (aRCC)
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
This observational study aims to describe demographic, clinical characteristics, treatment patterns outcomes of participants with advanced Renal Cell Carcinoma (aRCC) receiving either Nivolumab + Ipilimumab, or Pembrolizumab +…
- Trial name
- NCT06345183
- Testing
- Nivolumab + Ipilimumab combination therapy, Pembrolizumab + Lenvatinib combination therapy
- Where
- United States
- Volunteers
- 327 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma
Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors
To evaluate the clinically recommended dose of AG-013736 (Axitinib) in Japanese patients by reviewing the safety of AG-013736 (Axitinib) following single and multiple dosing.
- Trial name
- NCT00447005
- Testing
- Axitinib (AG-013736)
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
Advanced Breast Cancer
A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer
Docetaxol plus capecitabine regimen is the standard treatment for the anthracycline-pretreated patients with advanced breast cancer.
- Trial name
- NCT00717951
- Testing
- docetaxol, cisplatin, capecitabine
- Volunteers
- 120 people
- Sponsor
- Academy Military Medical Science, China
Carcinoma, Non-small Cell Lung Cancer
Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)
This is an open label, multi-center, randomized control phase II trial, to compare the efficacy and safety of sintilimab combined with anlotinib versus standard platinum-based chemotherapy as a first-line treatment in advanced…
- Trial name
- NCT04124731
- Testing
- sintilimab plus anlotinib, Chemotherapy
- Volunteers
- 98 people
- Sponsor
- Shanghai Chest Hospital
Pancreatic Cancer
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Determining the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of advanced or metastatic pancreatic cancer.
- Trial name
- NCT02117479
- Testing
- Ruxolitinib, Capecitabine
- Where
- 230 sites in United States, Australia and 10 more
- Volunteers
- 321 people
- Sponsor
- Incyte Corporation
Advanced Malignant Cancer
Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies
To evaluate the safety and tolerability of multiple administration of HRS-7053 in patients with advanced malignancies Determine the maximum tolerated dose (MTD, if possible) and the recommended dose for Phase II clinical studies…
- Trial name
- NCT05983146
- Testing
- HRS-7053 Injection
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer, Castrate Resistant Prostate Cancer
Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer
This is a clinical trial designed to quantify the immune response and determine the tolerability and side effects of sipuleucel-T when given in combination with ipilimumab for patients with advanced prostate cancer.
- Trial name
- NCT01832870
- Testing
- sipuleucel-T, ipilimumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Prostate Oncology Specialists, Inc.
Advanced Solid Tumors
Phase I Trial of Oral PX-866
This study is being conducted to determine the safety and maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.
- Trial name
- NCT00726583
- Testing
- PX-866
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Cascadian Therapeutics Inc.
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
This clinical trial studies radiolabeled glass beads (yttrium Y 90 glass microspheres) in treating patients with unresectable hepatocellular carcinoma.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT02072356
- Testing
- yttrium Y 90 glass microspheres, laboratory biomarker analysis, TheraSphere
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer, Prostate Cancer
Potential Vertebroplasty Use in the Treatment of Vertebral Metastasis From Breast and Prostate Cancer
The study aims to evaluate if adding vertebroplasty to radiotherapy, in the treatment of spine metastasis from breast and prostate cancer, is preferable to radiotherapy alone.
- Conditions
- Breast Cancer, Prostate Cancer, Vertebral Metastasis, Pain
- Trial name
- NCT00294151
- Testing
- Vertebroplasty
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Primary Amyloidosis of Light Chain Type
High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease
The aim of the study is to assess survival of patients with advanced cardiac AL amyloidosis treated with high cut-off hemodialysis (HCO-HD) combined with chemotherapy.
- Trial name
- DIACAL (NCT01531751)
- Testing
- High Cut-off Hemodialysis, Chemotherapy
- Where
- Italy
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
ALK Positive Non-small Cell Lung Cancer
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
This phase II study is aim to investigate the efficacy, resistance mechanism, safety profile of first-line lorlatinib in China advanced ALK+ non-small cell lung cancer (NSCLC).
- Trial name
- NCT06092086
- Testing
- Loratinib
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Guangdong Association of Clinical Trials
Advanced Solid Tumor
Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation
This is a phase 1 / 2 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of oral YL-15293 in patients with advanced solid tumors with KRAS mutation, so as to confirm the recommended phase 2…
- Trial name
- NCT05173805
- Testing
- YL-15293
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
UK Ibrance Patient Program (IPP) Study
What are the real-world treatment patterns, patients' characteristics, clinical outcomes and healthcare resource utilisation associated with palbociclib treatment in the 3 years following initiation in United Kingdom patients…
- Trial name
- ROIS (NCT03921866)
- Testing
- Palbociclib
- Where
- 8 sites in United Kingdom
- Volunteers
- 191 people
- Sponsor
- Pfizer
Advanced Solid Tumors
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
This is an open-label, single-arm, dose-escalation Phase I study to determine the maximum tolerated dose (MTD) of G-202 (mipsagargin) when administered once daily for 3 consecutive days of a 28-day cycle in patients with advanced…
- Trial name
- NCT01056029
- Testing
- G-202
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- GenSpera, Inc.
Pancreatic Cancer
Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer
The purposes of this study are to examine the effects of a new combination of drugs, celecoxib (Celebrex®) and irinotecan (CPT-11), with standard radiation therapy on people before they undergo surgery; to determine what effects…
- Trial name
- NCT00177853
- Testing
- celecoxib, irinotecan, concurrent radiotherapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Pittsburgh
Advanced Solid Tumors
MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.
The purpose of this study is to evaluate the safety, pharmacokinetics and Immunogenicity of Medi5083 alone or in combination with Durvalumab,Tremelimumab, and/or Docetaxel in adult subjects with advanced solid tumors.
- Trial name
- NCT03089645
- Testing
- MEDI5083 monotherapy, MEID5083 with Durvalumab or Tremelimumab, Medi5083 with Durvalumab and Docetaxel
- Where
- 8 sites in United States, Australia
- Volunteers
- 39 people
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.